CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Financials Charles River Laboratories International, Inc. Mexican S.E.
Equities
CRL *
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,917 MXN | -3.26% |
|
-3.26% | +0.20% |
| Jun. 13 | Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 | MT |
| Jun. 07 | The job report just threw a spanner in the works |  |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,416 | 12,366 | 18,969 | 11,086 | 12,127 | 10,790 | - | - |
| Enterprise Value (EV) 1 | 9,066 | 14,117 | 21,394 | 13,564 | 14,497 | 12,749 | 12,238 | 11,667 |
| P/E ratio | 29.9 x | 34.5 x | 49.5 x | 23 x | 25.6 x | 26.3 x | 21.6 x | 18.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.83 x | 4.23 x | 5.36 x | 2.79 x | 2.94 x | 2.56 x | 2.38 x | 2.21 x |
| EV / Revenue | 3.46 x | 4.83 x | 6.04 x | 3.41 x | 3.51 x | 3.02 x | 2.7 x | 2.39 x |
| EV / EBITDA | 15 x | 20.1 x | 24.3 x | 13.7 x | 14.3 x | 12 x | 10.5 x | 9.08 x |
| EV / FCF | 26.6 x | 37.1 x | 40.2 x | 46 x | 39.7 x | 29.1 x | 22.2 x | 19 x |
| FCF Yield | 3.75% | 2.69% | 2.49% | 2.17% | 2.52% | 3.44% | 4.5% | 5.27% |
| Price to Book | 4.55 x | 5.85 x | 7.46 x | 3.73 x | 3.37 x | 2.63 x | 2.27 x | 1.95 x |
| Nbr of stocks (in thousands) | 48,839 | 49,743 | 50,464 | 50,879 | 51,297 | 51,512 | - | - |
| Reference price 2 | 151.8 | 248.6 | 375.9 | 217.9 | 236.4 | 209.5 | 209.5 | 209.5 |
| Announcement Date | 2/11/20 | 2/17/21 | 2/16/22 | 2/22/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,621 | 2,924 | 3,540 | 3,976 | 4,129 | 4,221 | 4,535 | 4,874 |
| EBITDA 1 | 604.4 | 701.3 | 879.5 | 990.9 | 1,013 | 1,063 | 1,170 | 1,285 |
| EBIT 1 | 497.2 | 585 | 742.1 | 834 | 838.8 | 870.2 | 978.1 | 1,070 |
| Operating Margin | 18.97% | 20.01% | 20.96% | 20.97% | 20.31% | 20.61% | 21.57% | 21.95% |
| Earnings before Tax (EBT) 1 | 304.1 | 447.1 | 480.7 | 623 | 581.3 | 533.8 | 688.9 | 821.5 |
| Net income 1 | 252 | 364.3 | 391 | 486.2 | 474.6 | 409.8 | 512.1 | 596.3 |
| Net margin | 9.61% | 12.46% | 11.04% | 12.23% | 11.49% | 9.71% | 11.29% | 12.23% |
| EPS 2 | 5.070 | 7.200 | 7.600 | 9.480 | 9.220 | 7.954 | 9.717 | 11.49 |
| Free Cash Flow 1 | 340.4 | 380 | 532 | 294.9 | 365.4 | 438.4 | 550.4 | 615 |
| FCF margin | 12.99% | 13% | 15.03% | 7.42% | 8.85% | 10.38% | 12.14% | 12.62% |
| FCF Conversion (EBITDA) | 56.32% | 54.19% | 60.5% | 29.76% | 36.06% | 41.25% | 47.05% | 47.86% |
| FCF Conversion (Net income) | 135.08% | 104.31% | 136.07% | 60.65% | 76.98% | 106.96% | 107.48% | 103.14% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/11/20 | 2/17/21 | 2/16/22 | 2/22/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 905 | 913.9 | 973.1 | 989.2 | 1,100 | 1,029 | 1,060 | 1,027 | 1,013 | 1,012 | 1,022 | 1,071 | 1,113 | 1,095 | 1,105 |
| EBITDA 1 | 226.9 | 233.2 | 250.4 | 240.4 | 266.9 | 259.8 | 259.5 | 255.4 | 238.5 | 233.1 | 242.7 | 284.9 | 304.4 | 262.5 | 269.1 |
| EBIT 1 | 189.1 | 196 | 211.7 | 201.4 | 224.8 | 217.8 | 216.2 | 210.9 | 193.9 | 187.4 | 195.6 | 238.3 | 255.1 | 227.8 | 233.5 |
| Operating Margin | 20.89% | 21.45% | 21.75% | 20.36% | 20.44% | 21.16% | 20.4% | 20.54% | 19.14% | 18.53% | 19.13% | 22.25% | 22.91% | 20.81% | 21.13% |
| Earnings before Tax (EBT) 1 | 163.6 | 110.8 | 144.1 | 123.1 | 244.9 | 131 | 128.7 | 112.9 | 208.7 | 99.01 | 110.2 | 156 | 168.6 | 149.8 | 156.9 |
| Net income 1 | 137.6 | 93.02 | 109.3 | 96.47 | 187.4 | 103.1 | 97.02 | 87.39 | 187.1 | 67.33 | 83.64 | 121.6 | 131.4 | 116.8 | 117.4 |
| Net margin | 15.2% | 10.18% | 11.23% | 9.75% | 17.04% | 10.02% | 9.15% | 8.51% | 18.46% | 6.66% | 8.18% | 11.35% | 11.8% | 10.67% | 10.63% |
| EPS 2 | 2.670 | 1.810 | 2.130 | 1.880 | 3.650 | 2.010 | 1.890 | 1.690 | 3.620 | 1.300 | 1.675 | 2.320 | 2.578 | 2.160 | 2.210 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/16/22 | 5/4/22 | 8/3/22 | 11/2/22 | 2/22/23 | 5/11/23 | 8/9/23 | 11/8/23 | 2/14/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 1,650 | 1,751 | 2,425 | 2,477 | 2,370 | 1,959 | 1,447 | 877 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.73 x | 2.497 x | 2.758 x | 2.5 x | 2.339 x | 1.844 x | 1.237 x | 0.6823 x |
| Free Cash Flow 1 | 340 | 380 | 532 | 295 | 365 | 438 | 550 | 615 |
| ROE (net income / shareholders' equity) | 22.7% | 22% | 22.8% | 20.7% | 16.7% | 14.9% | 14.7% | 14.1% |
| ROA (Net income/ Total Assets) | 7.82% | 8.08% | 8.48% | 7.8% | 6.95% | 6.79% | 6.85% | 7% |
| Assets 1 | 3,222 | 4,508 | 4,612 | 6,232 | 6,830 | 6,032 | 7,473 | 8,519 |
| Book Value Per Share 2 | 33.40 | 42.50 | 50.40 | 58.40 | 70.10 | 79.80 | 92.30 | 107.0 |
| Cash Flow per Share 2 | 9.680 | 10.80 | 15.10 | 12.10 | 13.30 | 15.80 | 16.50 | 18.30 |
| Capex 1 | 141 | 167 | 229 | 325 | 319 | 302 | 326 | 350 |
| Capex / Sales | 5.36% | 5.7% | 6.46% | 8.17% | 7.71% | 7.14% | 7.2% | 7.18% |
| Announcement Date | 2/11/20 | 2/17/21 | 2/16/22 | 2/22/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
209.5
USD
Average target price
263.1
USD
Spread / Average Target
+25.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
- Stock Market
- Equities
- CRL Stock
- CRL * Stock
- Financials Charles River Laboratories International, Inc.
